ND-420 + cisplatin + fluorouracil

ND-420 + cisplatin + fluorouracil is a **combination regimen** used in oncology clinical trials, likely as part of a neoadjuvant or induction chemotherapy protocol. ND-420 is a small molecule agent under investigation, administered at 50 mg/m2, while cisplatin and fluorouracil are established chemotherapeutic drugs commonly used together in the treatment of solid tumors such as head and neck squamous cell carcinoma or certain types of breast cancer. The mechanism of ND-420 has not been publicly disclosed. Cisplatin acts mainly by crosslinking DNA, leading to apoptosis, while fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair. The combination aims to achieve synergistic cytotoxic effects against cancer cells. ND-420 is in phase 2 trials for cancer, given as part of an induction regimen[5]. Cisplatin and fluorouracil are both approved drugs used in numerous solid tumor indications.